Clarithromycin regresses endometriotic implants in rat endometriosis model

Area of Science:

• Reproductive Biology
• Pharmacology

Background:

• Endometriosis is a chronic, debilitating gynecological condition.
• Current treatments for endometriosis have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To investigate the efficacy of clarithromycin in a rat model of endometriosis.
• To explore the potential association between clarithromycin's effect and matrix metalloproteinase-9 (MMP-9) expression.

Main Methods:

• Surgically induced endometriosis in 27 rats, randomized into three groups.
• Group I received oral clarithromycin (100 mg/kg/day).
• Group II received leuprolide acetate (1 mg/kg s.c.).
• Group III served as the control group.
• Implant volumes and histopathological features were evaluated after 21 days.

Main Results:

• Significant reduction in endometriotic implant volumes in both clarithromycin and leuprolide acetate groups compared to control.
• Clarithromycin treatment led to a significant decrease in implant volume (from 62 to 26 mm³).
• Leuprolide acetate also significantly reduced implant volume (from 224 to 62 mm³).
• Histopathological scores differed significantly between groups.
• MMP-9 expression was significantly lower in the leuprolide acetate group but not affected by clarithromycin.

Conclusions:

• Clarithromycin demonstrates a significant regression effect on endometriotic implants in a rat model.
• The mechanism of action for clarithromycin's effect does not appear to involve modulation of MMP-9 expression.
• Further research is warranted to elucidate the precise mechanisms of clarithromycin in endometriosis treatment.